Akèy › Kansè trakt bilè › New York › New York City
Etid klinik pou Kansè trakt bilè nan New York City, NY
10 etid pou Kansè trakt bilè ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Ap rekriteFaz 3
- Memorial Sloan Kettering Cancer Center (Site 108), New York
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Ap rekriteFaz 3
- Research Site, New York
- Research Site, New York
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Ap rekriteFaz 1/2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324), New York
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Ap rekriteFaz 3
- Memorial Sloan Kettering Cancer Centers, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ap rekriteFaz 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
Etid Kansè trakt bilè nan lòt vil
- Houston, TX18 etid
- Los Angeles, CA11 etid
- Boston, MA11 etid
- Nashville, TN9 etid
- Baltimore, MD8 etid
- San Antonio, TX8 etid
- Washington, DC7 etid
- Arlington, VA7 etid
- Pittsburgh, PA7 etid
- Madison, WI6 etid
- Cleveland, OH6 etid
- Dallas, TX6 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.